BlackRock Health Sciences Opportunities Portfolio Class K (SHSKX)

NASDAQ · Mutual Fund · Delayed Price · Currency is USD
70.97
+0.48 (0.68%)
At close: Feb 13, 2026
Fund Assets6.47B
Expense Ratio0.75%
Min. Investment$5,000,000
Turnover43.00%
Dividend (ttm)7.02
Dividend Yield9.89%
Dividend Growth19.42%
Payout FrequencySemi-Annual
Ex-Dividend DateDec 9, 2025
Previous Close70.49
YTD Return0.57%
1-Year Return10.01%
5-Year Return29.41%
52-Week Low57.01
52-Week High72.67
Beta (5Y)n/a
Holdings161
Inception DateJun 8, 2016

About SHSKX

BlackRock Health Sciences Opportunities Fund Class K is a mutual fund that primarily targets long-term capital appreciation by investing at least 80% of its assets in equity securities of companies within the health sciences and related industries. The fund’s portfolio emphasizes both growth and value stocks across diversified market capitalizations, aiming to capture opportunities from the innovation and expansion within global healthcare sectors. Its holdings span leading biotechnology, pharmaceutical, medical device, and healthcare service companies, with notable concentrations in firms such as Eli Lilly and Company, Boston Scientific Corporation, and AbbVie Inc. The fund leverages investment expertise informed by scientific experience, seeking to deliver diversified returns with lower volatility compared to sector peers. Managed by BlackRock, the fund distinguishes itself through comprehensive research and a disciplined approach, while maintaining a competitive expense structure. Although the fund closely monitors environmental, social, and governance factors for transparency, it does not follow a specific ESG mandate. This fund holds a significant role in providing investors with access to innovative healthcare equities and exposure to a critical, ever-evolving industry that is central to global economic and societal well-being.

Fund Family BlackRock
Category Health
Performance Rating Above Average
Risk Rating Low
Stock Exchange NASDAQ
Ticker Symbol SHSKX
Index Russell 3000 Healthcare TR

Performance

SHSKX had a total return of 10.01% in the past year, including dividends. Since the fund's inception, the average annual return has been 17.96%.

Top 10 Holdings

47.30% of assets
NameSymbolWeight
Eli Lilly and CompanyLLY11.14%
Johnson & JohnsonJNJ8.58%
AbbVie Inc.ABBV4.08%
Abbott LaboratoriesABT4.00%
UnitedHealth Group IncorporatedUNH3.67%
Merck & Co., Inc.MRK3.65%
Gilead Sciences, Inc.GILD3.29%
Medtronic plcMDT3.14%
Amgen Inc.AMGN2.97%
Intuitive Surgical, Inc.ISRG2.79%
View More Holdings

Dividend History

Ex-DividendAmountPay Date
Dec 9, 2025$3.1808Dec 10, 2025
Jul 17, 2025$3.83665Jul 18, 2025
Dec 11, 2024$3.38503Dec 12, 2024
Jul 18, 2024$2.49135Jul 19, 2024
Dec 7, 2023$1.39964Dec 8, 2023
Jul 20, 2023$1.34151Jul 21, 2023
Full Dividend History